www.zerohedge.com By Tyler Durden
With shares already reflecting a post-COVID dearth of revenue streams, Pfizer’s growth outlook just took another hit as it halted development of its experimental weight-loss pill after a high rate of side effects appeared in a mid-stage study.
More than half of patients in the study had to stop taking danuglipron due to nausea and vomiting, according to a statement Friday.
Read Full Article Here…(zerohedge.com)
Home | Caravan to Midnight (zutalk.com)
Live Stream + Chat (zutalk.com)
